



February 10, 2020
Luxna Biotech Co., Ltd.

Notice of Fundraising

Luxna Biotech Co., Ltd., headquartered in Suita City, Osaka (President & CEO: Hideaki Sato) has devoted to developing novel oligonucleotide therapeutics with high safety and efficacy. We are pleased to announce that we have completed a third-party allocation of JPY 650 million ("Fundraising") in series A round. In addition to Osaka University Venture Capital Co., Ltd., headquartered in Suita City, Osaka (Representative Director: Toshiaki Jimbo), Nissan Chemical Corporation, headquartered in Nihonbashi, Chuo-ku, Tokyo (CEO: Kojiro Kinoshita), Summit Pharmaceuticals International Corporation, headquartered in Hitotsubashi, Chiyoda-ku, Tokyo (President & CEO: Kenichi Nakamura), Mizuho Capital Co., Ltd., headquartered in Uchisaiwai-cho, Chiyoda-ku, Tokyo (CEO: Yusuke Omachi), Senshu Ikeda Capital Co., Ltd., headquartered in Chaya-machi, Kita-ku, Osaka (CEO: Katsumi Hiramatsu) will join the Company's shareholders. In September and November 2019, the Company received a total of JPY 130 million in subordinated loan from Japan Finance Corporation to strengthen financial base. Luxna Biotech will use this capital to drive collaboration with pharmaceutical companies and academia by strengthening our platform technologies for oligonucleotide therapeutics.

In this funding, in addition to Osaka University Venture Capital Co., Ltd., which has been a lead investor since our start-up operation, we have welcomed two new venture capital (VC) investors: Mizuho Capital Co., Ltd., which has a proven track record of investing in drug discovery, and Senshu Ikeda Capital Co., Ltd., which supports innovation creation from Kansai area. In addition to VCs, Nissan Chemical Corporation and Summit Pharmaceuticals International Corporation, which have business partnerships with the Company, have also received investments. Going forward, we will develop our business globally at an early stage by deploying our oligonucleotide therapeutics platform technologies, while utilizing our shareholders' extensive knowledge and global network in the oligonucleotide therapeutics business arena. As part of our efforts to strengthen our capital structure, we are working to enhance capital by utilizing capital loans from the Japan Finance Corporation. Through these efforts, we will accelerate our activities to enhance joint drug discovery with pharmaceutical companies, promote the development of technology licensees, develop in-house programs spinal cord injury drugs and small cell lung cancer and treatment-resistant prostate cancer drugs followed by sublicensing.

Underwriting Companies

Osaka University Venture Capital Co., Ltd.
Mizuho Capital Co., Ltd.
Senshu Ikeda Capital Co., Ltd.
Nissan Chemical Corporation
Summit Pharmaceuticals International Corporation



About Luxna Biotech Co., Ltd.

Headquarters and Research Institute: 2-8 Yamadaoka, Suita City, Osaka

Representative: Hideaki Sato

Founded: December 2017

Website: <https://luxnabiotech.co.jp/en/>

Contact Info

Luxna Biotech Co., Ltd. Administration Department

E-mail info@luxnabiotech.co.jp:

EOD